Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2

Status

Unknown 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 92Polycystic Ovary Syndrome 10Neoplasm Metastasis 7Carcinoma, Ductal, Breast 5Infertility 4Carcinoma, Lobular 4Osteoporosis 3Neoplasms, Hormone-Dependent 3Neoplasms 3Breast Neoplasms, Male 3Advanced Breast Cancer 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Unilateral Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Osteitis Deformans 1Obesity 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Infertility, Female 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Hereditary Breast and Ovarian Cancer Syndrome 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

Fulvestrant 5Anastrozole 5Letrozole 3exemestane 2Goserelin 2ribociclib 1palbociclib 1entinostat 1elacestrant 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1RAD1901 1Paclitaxel 1Injections 1Gonadotropin-Releasing Hormone 1FCN-437c 1Everolimus 1Aromatase Inhibitors 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Advanced Breast Cancer × Letrozole × Clear all
NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
434 enrolled
Breast

Advanced Breast Cancer

NCT03966898 2021-06-02

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
426 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡